engleski

The frequency of CYP2D6 3* and 2D6 4* alleles in patients on psychoactive drug therapy

In the oxidative metabolism of majority of psychoactive drugs, the most important enzyme is the cytochrome P450 izoenzyme 2D6. The present study compared the frequency of CYP2D6 genotypes between psychiatric patients (n=32) and controls (n=53). Polymorphism of 2D6 gene (*3 and *4 alleles) was determined by PCR-SSCP. In controls, 0.9% and 17.0% of 2D6*3 and 2D6*4 alleles were found, respectively, among them 1.9% of heterozygotes for 2D6*3 and 29.5% for 2D6*4 allele. Homozygous genotype was only found for 2D64*allele, with the frequency of 2.3%. In the psychiatric group, no 2D6*3 allele but 28.6% of 2D6*4 allele were found, 30.8% of them as heterozygotes and 15.4% as homozygotes. The 2D6*4 homozygous genotype frequency was significantly higher than in controls (Chi:P=0.018). Although not significant, the 2D6*4 allele frequency was higher in psychiatric patients than in controls. In this group, significant homozygous genotype difference was also found. The incidence of poor metabolizer phenotype predicted from genotype, also showed a significant difference compared to controls (Chi: P=0.120). Comparison of the predicted phenotype with the treatment results showed a good agreement, suggesting that screening of psychiatric patients for CYP2D6 polymorphism may distinguish the metabolism-based therapeutic problems from drug sensitivity caused by other mechanisms.

CYP2D6; PCR-SSCP; psychoactive drug therapy

nije evidentirano